Carvedilol in glioma treatment alone and with imatinib in vitro

International Journal of Oncology

Volumn 36, Issue 4, 2010, Pages 857-866

  Erguven, Mine ^a,b   Yazihan, Nuray ^d   Aktas, Esin ^c   Sabanci, Akin ^a   Chiang, J L I ^f   Oktem, Gulperi ^e   Bilir, Ayhan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Centre de Recherche Scientifique et Technique pour les médicaments traditionnels   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d ANKARA UNIVERSITY   (Turkey)

^e EGE UNIVERSITY   (Turkey)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Autophagy; C6 glioma; Carvedilol; Imatinib mesylate; Mitochondria damage; Spheroid

Indexed keywords

BROXURIDINE; CARVEDILOL; CYCLIC AMP; IMATINIB;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DAMAGE; CELL KINETICS; CELL PROLIFERATION; CELL PROTECTION; CELL STRUCTURE; CELL VOLUME; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GLIOMA; GLIOMA CELL; IN VITRO STUDY; LABELING INDEX; MITOCHONDRION; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; SPHEROID CELL; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; BRAIN NEOPLASMS; CARBAZOLES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; CYCLIC AMP; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GLIOMA; PIPERAZINES; PROPANOLAMINES; PYRIMIDINES; RATS; SPHEROIDS, CELLULAR; TIME FACTORS;

EID: 77749335540     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000563     Document Type: Article

References (48)

1. Arora A and Scholar EM: Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315: 971-979, 2005.
2. Heinrich MC, Blanke CD, Druker BJ, et al: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20: 1692-1703, 2002.
3. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2000.
4. Yu C, Krystal G, Dent P, et al: Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in Bcr-Ablpositive human leukemia cells. Clin Cancer Res 8: 2976-2984, 2002.
5. Uziel O, Fenig E, Nordenberg J, et al: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 92: 1881-1891, 2005.
6. Deininger M, Buchdunger E and Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653, 2005.
7. Tarn C, Skorobogatko YV, Taguchi T, et al: Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signalingdependent and -independent mechanisms. Cancer Res 66: 5477-5486, 2006.
8. Kilic T, Alberta JA, Zdunek PR, et al: Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60: 5143-5150, 2000.
9. Krystal GW, Honsawek S, Litz J, et al: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6: 3319-3326, 2000.
10. Mitsiades CS, Sykoutri D, McMullan C, et al: Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 88: 5043-5044, 2003.
11. Kim SJ, Uehara H, Yazici S, et al: Targeting platelet-derived growth factor receptor on endothelial cells of multidrugresistant prostate cancer. J Natl Cancer Inst 98: 783-793, 2006.
12. O'Reilly T, Wartmann M and Maira SM: Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol 55: 307-317, 2005.
13. Lokker NA, Sullivan CM, Hollenbach SJ, et al: Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62: 3729-3735, 2002.
14. Dai H, Marbach P, Lemaire M, et al: Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304: 1085-1092, 2003.
15. Breedveld P, Beijnen JH and Schellens JH: Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27: 17-24, 2006.
16. 2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 49: 1722-1732, 2007.
17. Coats A: Use of carvedilol in the treatment of heart failure. Hosp Med 64: 288-291, 2003.
18. Book WM: Carvedilol: a nonselective beta blocking agent with antioxidant properties. Congest Heart Fail 8: 173-177. Erratum in: Congest Heart Fail 8: 240, 2002.
19. Stanojkovic TP, Zizak Z and Mihailovic-Stanojevic N: Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril. J Exp Clin Cancer Res 24: 387-395, 2005.
20. 2+ movement and cytotoxicity in human MG63 osteosarcoma cells. Basic Clin Pharmacol Toxicol 95: 59-65, 2004.
21. Bachmakov I, Werner U, Endress B, et al: Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol 20: 273-282, 2006.
22. Moe G: Carvedilol in the treatment of chronic heart failure. Expert Opin Pharmacother 2: 831-843, 2001.
23. Santini MT and Rainaldi G: Three-dimensional spheroid model in tumor biology. Pathobiology 67: 148-157, 1999.
24. Altinoz MA, Bilir A, Del Maestro RF, et al: Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro. Surg Neurol 65: 478-485, 2006.
25. Conger AD and Ziskin MC: Growth of mammalian multicellular tumor spheroids. Cancer Res 43: 556-560, 1983.
26. Kaygisiz Z, Erkasap N, Yazihan N, et al: Erythropoietin changes contractility, cAMP, and nitrite levels of isolated rat hearts. J Physiol Sci 56: 247-251, 2006.
27. Santos DL, Moreno AJ, Leino RL, et al: Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 185: 218-227, 2002.
28. Oliveira PJ, Bjork JA, Santos MS, et al: Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity.Toxicol Appl Pharmacol 200: 159-168, 2004.
29. Spallarossa P, Garibaldi S, Altieri P, et al: Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37: 837-846, 2004.
30. Oliveira PJ, Goncalves L, Monteiro P, et al: Are the antioxidant properties of carvedilol important for the protection of cardiac mitochondria? Curr Vasc Pharmacol 3: 147-158, 2005.
31. Kerkela R, Grazette L, Yacobi R, et al: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908-916, 2006.
32. Jacquel A, Herrant M, Legros L, et al: Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J 17: 2160-2162. Erratum in: FASEB J 17: 2347, 2003.
33. Sokolowska P and Nowak JZ: Constitutive activity of betaadrenergic receptors in C6 glioma cells. Pharmacol Rep 57: 659-663, 2005.
34. Grobben B, De Deyn PP and Slegers H: Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res 310: 257, 2002.
35. Jaiswal BS and Conti M: Calcium regulation of the soluble adenylyl cyclase expressed in mammalian spermatozoa. Proc Natl Acad Sci USA 100: 10676-10681, 2003.
36. Baillie GS and Houslay MD: Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr Opin Cell Biol 17: 129-134, 2005.
37. Hyde SC, Emsley P, Hartshorn MJ, et al: Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346: 362-365, 1990.
38. Shapiro AB and Ling V: Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 270: 16167-16175, 1995.
39. Sharom FJ, Yu X and Doige CA: Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem 268: 24197-24202, 1993.
40. Sharom FJ, Yu X, DiDiodato G, et al: Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. Biochem J 320: 421-428, 1996.
41. Vanderhoff BT, Ruppel HM and Amsterdam PB: Carvedilol: the new role of beta blockers in congestive heart failure. Am Fam Physician 58: 1627-1642, 1998.
42. Bornhäuser M, Pursche S, Bonin M, et al: Elimination of Imatinib mesylate and its metabolite N-desmethyl-Imatinib. J Clin Oncol 23: 3855-3856, 2005.
43. Sung CP, Arleth AJ, Eichman C, et al: Carvedilol, a multipleaction neurohumoral antagonist, inhibits mitogen-activated protein kinase and cell cycle progression in vascular smooth muscle cells. J Pharmacol Exp Ther 283: 910-917, 1997.
44. Fujio H, Nakamura K, Matsubara H, et al: Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 47: 250-255. Erratum in: J Cardiovasc Pharmacol 47: table of contents, 2006.
45. Ertmer A, Huber V, Gilch S, et al: The anticancer drug imatinib induces cellular autophagy. Leukemia 21: 936-942, 2007.
46. Carew JS, Nawrocki ST and Cleveland JL: Modulating autophagy for therapeutic benefit. Autophagy 3: 464-467, 2007.
47. Carew JS, Nawrocki ST, Kahue CN, et al: Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110: 313-322, 2007.
48. Takagi A, Watanabe M, Ishii Y, et al: Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features. Anticancer Res 27: 45-53, 2007.